Navigation Links
ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
Date:2/19/2009

er 31, 2008, was $1.9 million (or $0.06 per share) and $30.7 million (or $0.93 per share), respectively, compared with a net loss of $9.9 million (or $0.30 per share) and $38.2 million (or $1.29 per share) for the same periods in 2007. At December 31, 2008, ISTA had cash and short-term investments of $53.0 million.

2009 Financial Outlook

  • We expect our net revenue for 2009 will be approximately $92 to $97 million. We do not expect a generic to Xibrom in 2009. Our net sales are seasonal, with first quarter net sales typically being the lowest of the year and less than the prior quarter.
  • We expect our gross margin to be 70% to 73% in 2009. We expect our gross margin to be at the lower end at the beginning of the year and increasing to the higher end by year end 2009, due to the timing of certain manufacturing expenses in 2009.
  • We expect to be approximately operating income breakeven in 2009.
  • We expect our net loss for 2009 will be approximately $7 to $10 million, due to interest and related expenses.
  • Depending upon the progress of our clinical and pre-clinical programs, we expect our research and development expenses in 2009 to be in the range of $20 to $25 million and include costs associated with supporting the Bepreve NDA filing, milestones we have paid or expect to pay to Senju for the acceptance and approval of Bepreve, the Xibrom QD confirmatory study, T-Pred study completion, and a low-concentration version of Xibrom for dry eye.
  • We expect to end 2009 with a cash balance of $35 to $45 million, including cash drawn on our Silicon Valley Bank revolving credit facility, subject to change due to fluctuations in working capital.

Conference Call

ISTA will host a conference call with a simultaneous webcast today, February 19, 2009, at 5:00 PM Eastern Time, to discuss its fourth qu
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... MarketsandMarkets recently conducted a study on ... 3D rendering; Layout and Animation; Image Reconstruction]: Global ... which analyzes and studies the major market drivers, ... Eastern Europe, Middle East and Africa, Asia-Pacific and ... landscape of the 3D imaging market, providing an ...
(Date:7/13/2014)... July 13, 2014 The Pearland, Texas location ... in age from four months to 12 years of age ... classes to birthday parties and Summer Camps, is now under ... Gym of Pearland after spending over six years at ... including Gym Director. , Berry has over ten years ...
(Date:7/13/2014)... 13, 2014 Recently, 2014QuinceaneraDresses.com, the ... unveiled its new range of gorgeous Quinceanera ... the demand for elegant Quinceanera outfits is huge. ... items. All the company’s newly released dresses are ... are all elegant and vivid. , It ...
(Date:7/13/2014)... 2014 Fadhits.com is popular among worldwide ... are extremely beautiful. Recently, the company has announced its ... 2014. What’s more, all these outfits are available at ... , Additionally, the supplier is now offering similar discounts ... dresses, it has many other designs for sale, including ...
(Date:7/13/2014)... COPENHAGEN, July 13, 2014 A decreased ability ... cognitive impairment and Alzheimer,s disease, while examinations of ... a protein associated with Alzheimer,s, in the brain, ... reported today at the Alzheimer,s Association International Conference ... of the studies, the decreased ability to identify ...
Breaking Medicine News(10 mins):Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7
... New findings show that treatment with a specific alpha ... for men with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). ... relaxing the muscles in the bladder neck and prostate. ... States, the EU and Japan to treat painful symptoms ...
... 11 (HealthDay News) -- Some men with enlarged prostate ... severe complications as a result, according to a new ... for enlarged prostate, the rate of men operated on ... the rate of discharges for men for enlarged prostate ...
... NJIT and UMDNJ have executed a license agreement with The ... on which a patent is pending. The tonometer ... Gordon Thomas, PhD, and Robert Fechtner, MD, director of the ... was a member of the research team. "We ...
... address a major new risk for the global supply ... the supply chain as pharmaceutical companies increasingly outsource the ... topic of the cover story in the current edition ... C&EN Senior Editor Rick Mullin explains that ...
... first time, researchers at McMaster University have conclusive evidence ... and behaviour. The findings are important because several ... are frequently associated with anxiety or depression. In addition ... as late onset autism, may be associated with an ...
... new study led by the University of Leicester has concluded ... in a doctor,s surgery helps to reduce emergency hospital admissions. ... Sciences at the University of Leicester revealed a correlation between ... hospital admissions. The research, published in Emergency Medical ...
Cached Medicine News:Health News:Experimental treatment offers relief from painful prostate condition 2Health News:Fewer Men Having Surgery to Treat Enlarged Prostate: Study 2Health News:NJIT and UMDNJ license personal tonometer technology for innovative glaucoma testing 2Health News:That anxiety may be in your gut, not in your head 2Health News:Patients who see preferred doctor less likely to go for emergency hospital admission 2
(Date:7/11/2014)... Australia , July 11, 2014  Australian drug ... announced that it has raised A$19.3 million via a ... Europe , the U.S., Asia ... A$3 million from a share purchase plan (SPP) to ... million will be made in two tranches. ...
(Date:7/11/2014)... 2014 According to a new ... Market (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) - ... 2013-2019" the global endoscopy devices market was valued at ... grow at a CAGR of 6.8% from 2013 to ... billion in 2019. Browse the full Endoscopy ...
(Date:7/11/2014)... , July 11, 2014  Veran ... company, announced today the positive, cost-effective final ... innovative SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous ... a percutaneous approach to biopsy when a ... patients and physicians experience positive financial outcomes ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Veran Medical Publishes Lung Cancer Patient Management Study 2
... Extrovertic and Virilion ... , to help healthcare companies engage consumers in an increasingly ... ) , "Innovating to meet the perpetually evolving needs ... Dorothy Wetzel, co-founder and executive marketer at Extrovertic. "Doing it ...
... 28 Southern California-based philanthropy Free Wheelchair Mission ... Blessing International,s annual giving catalog. Called "Relief ... 19 humanitarian outreach operations, supporting causes including hunger ... , The two international nonprofits have collaborated since ...
Cached Medicine Technology:Joint Venture Formed to Help Health Marketers Navigate Social Media Environment 2OC-Based Charity Teams with International Relief Organization in Holiday Fundraising Drive 2
For the qualitative and semi-quantitative measurement of RF in human serum....
... The Newmarket Laboratories RPR kits use ... of lipid antigens, which will combine ... or plasma. The particles are suspended ... eliminate non - specific reactions. Positive ...
Rapid Plasma Reagin (RPR) set is a non-treponemal flocculation test that is,used for the qualitative and semi-quantitative determination of reagin,antibodies in serum or plasma from persons with syph...
... For use as a quality ... IgG antibody to Toxoplasma gondii ... rubella virus (rubella IgG), IgG ... and IgG antibody to herpes ...
Medicine Products: